Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 289

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 289
---
 Company received
$250,000 under such Bridge Loans.

Between December 2023
and January 2024, we entered into the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate amount of $150,000 from
certain lenders, including certain related parties. In October 2024, we amended the 2024 Loan Agreements pursuant to which the 2024 Loan
Agreements have been extended until August 31, 2025, and shall bear interest at 8% per annum until maturity commencing as of September
1, 2024. Furthermore, upon the occurrence of a Qualifying IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase
such number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium based on a price per share
equal to 75% of the lowest price per share of the Ordinary Shares during the first five trading days following the consummation of such
initial public offering.

In April 2025, we entered
into bridge loan agreements, or the 2025 Loan Agreements, pursuant to which we obtained a bridge loans in the aggregate amount of $110,000
from certain lenders, including certain related parties. The loans pursuant to the 2025 Loan Agreements bear interest at a rate of 8%
per annum until maturity. Pursuant to the terms of the 2025 Loan Agreements, we also agreed to pay the lenders an additional risk premium
equal to 50% of their respective loan amount. The loans under the 2025 Loan Agreements mature upon the earlier of August 31, 2025 or
the date of consummation of a Qualified IPO (as such term is defined in the 2025 Loan Agreements). Furthermore, upon the occurrence of
a Qualifying IPO, the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times their
respective loan amount in addition to a risk premium based on a price per share equal to 75% of the lowest price per share of the Ordinary
Shares during the first five trading days following the consummation of such Qualifying IPO.

The sales of the above securities
were deemed to be exempt from registration under the Securities Act because they were made outside of the United States of America to
certain non-U.S. individuals or entities pursuant to Regulation S or, in reliance upon the exemption from registration provided under
Section 4